DYRK1B and leukemia: Analysing the expression of potent kinase off-targets of PARP inhibitors in haematological cancers using canSAR53 reveals that DYRK1A and DYRK1B are overexpressed at the mRNA level in several types of leukaemia and lymphoma (Supplementary Figs. 3–6).